New name expresses the Company’s vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world – and its mission to accelerate the development of life-changing medicines, by investing in science and technology

新名称表达了该公司领导下一个医学时代的愿景-从日本到日本，再延伸到世界-以及通过投资科学和技术加速发展改变生命的药物的使命

Sosei Group and its subsidiaries, Heptares Therapeutics and Idorsia Pharmaceuticals Japan and Korea, have all been renamed under the Nxera Pharma brand

Sosei集团及其子公司Heptares Therapeutics和Idorsia Pharmaceuticals Japan和Korea均已更名为Nxera Pharma品牌

Tokyo, Japan and Cambridge, UK, 1 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce the launch of its new company name, having received approval at the 34th Ordinary General Meeting of Shareholders held on 27 March 2024.

日本东京和英国剑桥，2024年4月1日——Nxera Pharma Co.，Ltd.（“Nxera”或“该公司；TSE 4565）-以前称为Sosei Group或Sosei Heptares-很高兴宣布推出其新公司名称，并在2024年3月27日举行的第34次股东常会上获得批准。

The Company’s new website can be found at www.nxera.life.

该公司的新网站可以在www.nxera.life上找到。

The Group name and those of its subsidiaries have changed as follows:

集团名称及其子公司名称变更如下：

Old name

旧名称

New name

新建名称

Sosei Group Corporation

Sosei集团公司

Nxera Pharma Co., Ltd.

Nxera制药有限公司

Idorsia Pharmaceuticals Japan Ltd

Idorsia Pharmaceuticals日本有限公司

Nxera Pharma Japan Co., Ltd.

Nxera制药日本有限公司

Idorsia Pharmaceuticals Korea Co., Ltd

Idorsia Pharmaceuticals韩国有限公司

Nxera Pharma Korea Co., Ltd.

Nxera制药韩国有限公司

Heptares Therapeutics Ltd.

Heptares Therapeutics有限公司

Nxera Pharma UK Limited

Nxera Pharma UK Limited

Chris Cargill, President & CEO of Nxera Pharma, commented: “Our name change from Sosei Group to Nxera Pharma marks a pivotal moment in our Company’s journey. It follows the significant growth and development of the business, which has been accelerated through several key strategic acquisitions in recent years, including Heptares Therapeutics in 2015 and the Idorsia Pharmaceuticals Japan and Korea businesses in 2023.

Nxera Pharma总裁兼首席执行官克里斯·卡吉尔（ChrisCargill）评论道：“我们从Sosei Group更名为Nxera Pharma，标志着公司发展历程中的一个关键时刻。随着业务的显著增长和发展，近年来通过几项关键的战略收购，包括2015年的Heptares Therapeutics和2023年的Idorsia Pharmaceuticals日韩业务，业务得到了加速发展。

These acquisitions have transformed the business into an integrated, technology powered, commercial-stage biopharmaceutical company focused on accelerating the development of life-changing medicines for patients in Japan and globally, by investing in science and technology..

这些收购将该业务转变为一家综合性、技术驱动的商业化生物制药公司，专注于通过投资科学技术，加速日本和全球患者改变生命的药物的开发。。

“The Company decided that now is the optimal time to unify the business under a new name and bold brand. The name ’Nxera’ derives from the words ‘Next’ and ‘Era’ and our new motto – ‘Our Life’s Work is Life Itself’ – expresses our determination to lead the next era of medicine, leveraging our industry leading NxWave™ platform to drive advancements in our core disease areas of neurology, GI and immunology, metabolic disorders and rare diseases, in pursuit of new medicines for patients.”.

“公司决定，现在是将业务统一到一个新名称和大胆品牌下的最佳时机。“Nxera”这个名称来源于“下一个”和“时代”，我们的新座右铭——“我们生命的工作就是生命本身”——表达了我们领导下一个医学时代的决心，利用我们业界领先的NxWave™平台，推动我们在神经病学、胃肠道和免疫学、代谢紊乱和罕见疾病等核心疾病领域的进步，为患者寻求新药。”。

Shinichi Tamura, Chairman of Nxera Pharma, added: “When I founded Sosei in 1990, I had a clear vision to create Japan’s first global biotechnology champion. I am extremely proud of what we have achieved since then and truly excited about what we, as Nxera Pharma, can deliver in the future, to our patients, partners, employees and shareholders, as this vision becomes a reality..

Nxera Pharma董事长田村信一（Shinichi Tamura）补充道：“当我于1990年成立Sosei时，我有一个清晰的愿景，即创建日本第一个全球生物技术冠军。我为我们自那时以来取得的成就感到无比骄傲，也为我们作为Nxera Pharma在未来能够为我们的患者、合作伙伴、员工和股东提供的服务感到兴奋，因为这一愿景成为现实。。

“Our Company would not be where it is today without the dedication and effort of our truly international team, primarily in Japan and the UK, but also with key groups in South Korea and Switzerland. I would like to express my sincere gratitude to all the ambitious and highly talented people who have contributed to and shaped our journey, positioning Nxera Pharma at the forefront of the next generation of biopharmaceutical companies in Japan improving the health of patients globally.”.

“如果没有我们真正国际化的团队（主要是日本和英国的团队，以及韩国和瑞士的关键团队）的奉献和努力，我们的公司将不会达到今天的水平。我要衷心感谢所有雄心勃勃和才华横溢的人，他们为我们的旅程做出了贡献和塑造，将Nxera Pharma定位在日本下一代生物制药公司的前列，改善全球患者的健康。”。

–END–

–结束–

About Nxera Pharma

关于Nxera Pharma

Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

Nxera Pharma（前身为Sosei Heptares）是一家以技术为动力的生物制药公司，致力于开发新的专业药物，以改善日本和全球需求未得到满足的患者的生活。

In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWaveTM” platform to provide a sustainable source of best- or first-in-class candidates..

除了在日本商业化的几种产品外，我们还与领先的制药和生物技术公司合作，推进了从发现到临床后期的30多个活跃项目的广泛渠道。这条管道的重点是解决神经内科、胃肠道和免疫学、代谢紊乱和罕见疾病等一些发展最快的医学领域的主要未满足需求，并利用我们独特且行业领先的基于GPCR靶向结构的药物发现“NxWaveTM”平台的强大功能，为最佳或一流候选人提供可持续的来源。。

Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

Nxera在东京和大阪（日本）、伦敦和剑桥（英国）、巴塞尔（瑞士）和首尔（韩国）的关键地点拥有350多名人才，并在东京证券交易所上市（股票代码：4565）。

For more information, please visit www.nxera.life

有关更多信息，请访问www.nxera.life

LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

领英：@NxeraPharma[UNK]X:@Nxera Pharma/UNK]YouTube：@NxeraPharma

Enquiries:

查询：

Nxera – Media and Investor Relations

Nxera–媒体与投资者关系

Kentaro Tahara, VP Investor Relations and Corporate Strategy

投资者关系和公司战略副总裁Kentaro Tahara

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

Shinichiro Nishishita，投资者关系副总裁，监管披露负责人

Maya Bennison, Communications Manager

Maya Bennison，通信经理

+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life

+81（0）3 5210 3399[未知]+44（0）1223 949390[未知]IR@Nxera.life

MEDiSTRAVA Consulting (for International Media)

MEDiSTRAVA Consulting（国际媒体）

Mark Swallow, Frazer Hall, Erica Hollingsworth

Mark Swallow，Frazer Hall，Erica Hollingsworth

+44 (0)203 928 6900 | Nxera@medistrava.com

+44（0）203 928 6900[未知]Nxera@medistrava.com

Forward-looking statements

前瞻性声明

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors.

本新闻稿包含前瞻性声明，包括有关产品发现、开发和商业化的声明。各种风险可能导致Nxera Pharma Group的实际结果与前瞻性声明中明示或暗示的结果存在重大差异，包括：临床开发计划中的不利结果；未获得发明专利保护；由第三方拥有或控制的专利施加的商业限制；依赖战略联盟伙伴开发和商业化产品和服务；由于开发工作，难以或延迟获得监管部门对市场产品和服务的批准；需要大量资金进行研究和开发以及扩大商业化活动；以及竞争对手的产品计划。

As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise..

由于这些因素，提醒潜在投资者不要依赖任何前瞻性陈述。无论是由于新信息、未来事件还是其他原因，我们都没有更新或修改任何前瞻性声明的意图或义务。。